Download pdf
The Effectiveness of Ketamine Treatment on Depression
- 1 Shanghai Pinghe Bilingual School
* Author to whom correspondence should be addressed.
Abstract
As the diagnosis rate of depression continues to rise, effective treatment options for this condition have become one of the most researched areas in the field. Earlier antidepressants were primarily developed based on mechanisms that involve regulating imbalanced neurotransmitters. For example, the widely known Selective Serotonin Reuptake Inhibitors (SSRIs) and various tricyclic antidepressants work by adjusting the concentration of different neurotransmitters, such as dopamine and norepinephrine, in the synaptic cleft to alleviate depressive symptoms. Additionally, many therapeutic approaches have been developed and applied based on the widely accepted hormone hypothesis and neurotrophic factor hypothesis. Ketamine, a drug traditionally used as an anesthetic, has recently been discovered to possess antidepressant properties. Its efficacy and underlying neuroscientific mechanisms are currently under investigation. Unlike earlier antidepressants, Ketamine produces significant antidepressant effects within a short time after administration. Multiple studies have suggested that Ketamine's rapid and effective therapeutic results may be based on entirely new antidepressant mechanisms and targets that have yet to be fully understood. This provides a new solution for the treatment of treatment-resistant depression and offers new hope to patients who have tried various treatments without success. In this literature review, Ketamine's therapeutic effects and its underlying mechanisms will be thoroughly examined. The content will be divided into three sections: significant antidepressant effects, underlying principles and mechanisms, and factors relevant to the improvement of Ketamine therapy.
Keywords
depression, Ketamine, treatment resistance
[1]. Boku, S., Nakagawa, S., Toda, H. and Hishimoto, A. (2017). Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences, 72(1), 3–12.
[2]. Hirschfeld, R.M. (2000). History and evolution of the monoamine hypothesis of depression. Journal of clinical psychiatry, 61(6), 4-6.
[3]. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J. and Monteggia, L.M. (2002). Neurobiology of depression. Neuron, 34(1), 13-25.
[4]. Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S. and Hu, H. (2018). Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature, 554(7692), 317-322.
[5]. Serafini, G., Howland, R., Rovedi, F., Girardi, P. and Amore, M. (2014). The role of Ketamine in treatment-resistant depression: a systematic review. Current neuropharmacology, 12(5), 444-461.
[6]. Mandal, S., Sinha, V.K. and Goyal, N. (2019). Efficacy of Ketamine therapy in the treatment of depression. Indian journal of psychiatry, 61(5), 480-485.
[7]. Phillips, J.L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M. and Blier, P. (2020). Single and repeated Ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology, 45(4), 606-612.
[8]. Anand, A., Mathew, S.J., Sanacora, G., Murrough, J.W., Goes, F.S., Altinay, M. and Hu, B. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388(25), 2315-2325.
[9]. Fuchikami, M., Thomas, A., Liu, R., Wohleb, E.S., Land, B.B., DiLeone, R.J. and Duman, R.S. (2015). Optogenetic stimulation of infralimbic PFC reproduces Ketamine’s rapid and sustained antidepressant actions. Proceedings of the National Academy of Sciences, 112(26), 8106-8111.
[10]. Moda-Sava, R.N., Murdock, M.H., Parekh, P.K., Fetcho, R.N., Huang, B.S., Huynh, T.N. and Liston, C. (2019). Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science, 364(6436), eaat8078.
[11]. Loo, C., Glozier, N., Barton, D., Baune, B.T., Mills, N.T., Fitzgerald, P. and Rodgers, A. (2023). Efficacy and safety of a 4-week course of repeated subcutaneous Ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. The British Journal of Psychiatry, 223(6), 533-541.
[12]. Brachman, R.A., McGowan, J.C., Perusini, J.N., Lim, S.C., Pham, T.H., Faye, C. and Denny, C.A. (2016). Ketamine as a prophylactic against stress-induced depressive-like behavior. Biological psychiatry, 79(9), 776-786.
[13]. Katalinic, N., Lai, R., Somogyi, A., Mitchell, P.B., Glue, P. and Loo, C.K. (2013). Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry, 47(8), 710-727.
[14]. Bratsos, S. and Saleh, S.N. (2019). Clinical efficacy of Ketamine for treatment-resistant depression. Cureus, 11(7).
Cite this article
Liu,Y. (2024). The Effectiveness of Ketamine Treatment on Depression. Communications in Humanities Research,40,150-156.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of 3rd International Conference on Interdisciplinary Humanities and Communication Studies
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).